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continuous combination prescriptions (subgroup) from a managed care organization 
health care system perspective. METHODS: Using the Integrated Health Care Infor-
mation Services National Managed Care Benchmark Database from January 19997-
June 2007, we followed newly-diagnosed, HCV-infected patients with cirrhosis for 
the occurrence of end-staged liver diseases (ESLD), starting from the date of their 
ﬁrst prescriptions. For each patient, we measured effectiveness (Ei) as time to ESLD 
occurrence or censored, and costs (Ci) as the sum of pharmacy, outpatient and 
inpatient costs incurred in the follow up (2007 US dollars). Individual patient’s net 
beneﬁt was calculated as lambda times Ei minus Ci, and the net beneﬁt regression 
framework was employed to determine the cost-effectiveness of antiviral therapy and 
the importance of covariates on the incremental net beneﬁt of an intervention control-
ling for patient-related characteristics. The inverse probability of censored weighting 
technique was used to account for potential bias due to censored cost and effectiveness 
data. RESULTS: The results found that, at a number of lambda values qUS$10,000, 
combination antiviral therapy was more cost effective than no treatment in base case 
analysis. In subgroup analysis, continuous antiviral therapy was cost effective than 
no treatment at lambda value qUS$1000,000. Time of HCV diagnosis, HIV co-infec-
tion and prior gastroenterologist visits were potentially important covariates on 
the incremental net beneﬁt of treatment. CONCLUSIONS: From the standpoint of 
cost-effectiveness, continuation of antiviral therapy should consider the variability 
in early viral response because treatment beyond 12 weeks is no recommended 
for genotype 1, HCV-infected patients when achieving sustained viral response is 
unlikely.
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OBJECTIVES: To evaluate long-term cost-effectiveness of the treatment of CHB 
HBeAg-positive and -negative patients with telbivudine compared with lamivudine. 
METHODS: The study was conducted from China’s social health insurance perspec-
tive over a lifetime horizon using a Markov model. Individual patient data (age, 
gender, virological, serological and biochemical response and resistance to telbivudine 
versus lamivudine) after 104 weeks from the multinational GLOBE registration trial 
were applied. Disease progression from CHB to other health states was derived from 
literature. Economic outcomes, including China-speciﬁc data for life expectancy, 
utility and drug costs were applied. The annual medical expenditure was calculated 
with 599 community patients with CHB-related diseases in Beijing and Guangzhou 
cities of China and data were also retrieved from literature. Drug treatment of telbi-
vudine or lamivudine treatment is ceased upon achieving chronic hepatitis HBeAg-, 
HBsAg-. All costs were valued in Chinese-yuan, year 2007 values. Costs and outcomes 
were discounted at 3% per annum. Sensitivity analysis was conducted to evaluate 
uncertainty in study results. RESULTS: Compared with lamivudine, the incremental 
cost for 1 additional QALY gained with telbivudine in treating HBeAg-positive and 
-negative CHB were 13,361 yuan (US$1,965) and 62,999 yuan (US$9,265) in Beijing, 
as well 12,078 yuan (US$1,776) and 65,864 yuan (US$9,686) in Guangzhou, respec-
tively. According to national economic burden of CHB-related diseases retrieved from 
literature, the ICER with telbivudine vs lamivudine were 3,170 yuan (US$466) and 
70,420 yuan (US$10,356) for HBeAg-positive and -negative CHB, respectively. CON-
CLUSIONS: Among CHB patients, treatment with telbivudine is cost effective as 
compared to lamivudine, based on the World Health Organization’s recommended 
maximum willingness to pay threshold.
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OBJECTIVES: Rotavirus (RV) is a major cause of gastroenteritis (GE) in infants but 
can be prevented by vaccination. The study objective was to estimate the cost effective-
ness of universal rotavirus vaccination of infants from an Irish Healthcare payer per-
spective. METHODS: A published Markov model, calibrated to observed Irish 
epidemiological data was used. A cohort of 70,600 newborns was followed over ﬁve 
years during which the seasonality of infection and protective effects of breastfeeding 
were captured. Routine vaccination with the oral 2- dose vaccine RIX 4414 was 
compared with no vaccination. Efﬁcacy from a European phase-III trial (102247) 
showed 96% and 86% against severe RVGE and 100% and 92% against hospitalisa-
tions due to RV in the ﬁrst and second years post vaccination respectively. Costs were 
from published sources in 2007 prices. Utilities came from a UK study of physician 
scores using the EQ-5D questionnaire. Costs and effects, discounted at 3.5%, were 
assessed over lifetime. Sensitivity analyses were conducted. RESULTS: The model 
estimated that 14,700 GP visits, 4,000 A&E visits, 3,400 hospitalisations and 840 
nosocomial cases occurred in the birth cohort at a cost of a7.3m. With a coverage 
rate of 87% the number of GP and hospital visits could be reduced by 82% with 
vaccination. Cost effectiveness was estimated at a29,398 per QALY. These results 
were driven by the high rate of hospitalisation due to RV. The results were most sensi-
tive to the cost of vaccination and hospitalisations, incidence of RV and hospitalisa-
tions and the discount rate. CONCLUSIONS: Rotavirus imposes a signiﬁcant ﬁnancial 
burden on the Irish health care system. Universal vaccination of infants is a cost-
 effective approach to reducing this burden.
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OBJECTIVES: To estimate the clinical and economic impact of vaccinating a birth 
cohort with the newly licensed 10-valent pneumococcal non-typeable haemophilus 
inﬂuenzae protein-D conjugate vaccine (PHiD-CV) compared with the 13-valent pneu-
mococcal candidate vaccine (PCV-13) over lifetime. METHODS: We developed an 
age-compartmental, deterministic, and static Markov model to project the impact of 
pneumococcal vaccination on the incidence of pneumococcal infections from birth 
through lifetime in speciﬁc age–time units (months). The disease types modeled include 
invasive pneumococcal disease (IPD), community acquired pneumonia (CAP) and 
acute otitis media (AOM), assuming 11 health states per condition. Serotype distribu-
tions per disease type and age group were incorporated. Costs, health gains and cost-
effectiveness were estimated. A 4-dose (31) schedule is assumed for both vaccines 
with 100% vaccine coverage. All analyses were performed from the Canadian health 
care system perspective assuming a price parity of $70 per dose. The model uses 
Canada speciﬁc epidemiological data. Both outcomes and cost were discounted at 
3.5%. Various sensitivity analyses were performed to assess the impact of changes in 
the key assumptions of the model. RESULTS: Compared with PCV-13, vaccinating a 
birth cohort of 340,000 with PHiD-CV in Canada is expected to prevent 92,026 
additional AOM myringotomies and 108,978 ambulatory visits due to AOM over 
lifetime. The impact of the two vaccines on IPD is projected to be comparable. At 
price parity of $70 per dose, the total savings to the Canadian health care system over 
the lifetime of the cohort is projected to be $58.7M for PHiD-CV compared to PCV-
13. Sensitivity analyses indicate that AOM and bacteraemia have the biggest impact 
on the model. CONCLUSIONS: Overall, the clinical beneﬁts of the two vaccines are 
comparable on IPD. QALYs are improved for PHiD-CV compared to PCV-13 because 
of the greater impact on AOM. PHiD-CV is projected to be cost-saving to the Cana-
dian health care system compared to PCV-13.
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OBJECTIVES: To determine the cost-effectiveness of pneumococcal non-typeable 
Haemophilus inﬂuenzae protein-D conjugate vaccine (PHiD-CV) when compared with 
7-valent pneumococcal conjugate vaccine (PCV-7) and with no vaccination for the 
prophylaxis of invasive (ID) and non-invasive pneumococcal diseases in Poland. 
METHODS: A Markov cohort model was used with a starting birth cohort of 393 
506 infants. The Streptococcus pneumoniae serotype distribution from Czech Repub-
lic setting was selected as a proxy for Polish data. The effectiveness and safety data 
came from a meta-analysis of clinical trial results. Limited cross-protection of sero-
types 6A and 19A, herd protection and serotype replacement were included into the 
model design. Ten years time horizon (the period of direct vaccine effect) and 96% 
vaccine coverage rate were considered. Direct medical costs were collected during 
January-March, 2009 from a public payer’s and patient’s perspective. Price parity 
between vaccines was assumed. Sensitivity analysis was carried out. Annual discount 
rate for cost and effect was 5.0% and 3.5% respectively. RESULTS: Base-case analysis 
of PHiD-CV shows that mass vaccination of the birth cohort reduced the number of 
ID by 120, pneumonia by 17,102, and acute otitis media events by 113,768 cases over 
10 years. When compared with PCV-7 and no vaccination, PHiD-CV offered a Quality 
Adjusted Life Year gain (QALY) of 0.0045 and 0.0068 per vaccinated child respec-
tively. Prophylaxis with PHiD-CV instead of PCV-7 induced cost savings of 39.97 PLN 
per child. Vaccination with PHiD-CV dominated PCV-7 but when compared with no 
vaccination an incremental cost per QALY was estimated at 54,549 PLN. Sensitivity 
analysis showed consistency in the results. A few analysis limitations were identiﬁed 
such as length of vaccine protection and reliable serotype distribution data. CONCLU-
SIONS: Compared with no vaccination the model indicates that PHiD-CV is cost-
effective in Poland and has superior economic proﬁle to PCV-7.
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OBJECTIVES: National 7-valent pneumococcal vaccination (PCV7) was introduced 
in Greece in 2006. In May 2009 a 10-valent (PCV10) vaccine became available. A 
13-valent (PCV13) vaccine is expected in late 2009. This study aims to assess the 
clinical and economic beneﬁts of national immunization with PCV13 compared to 
PCV7 and PCV10 from the national health system perspective. METHODS: Using an 
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EXCEL decision analytic model we considered disease incidence and sequelae, sero-
type coverage and health care utilization to compare costs and impact of PCV13 vs. 
PCV10, vs. PCV7 and vs. no vaccination on invasive pneumococcal disease (IPD), 
pneumonia, and otitis media, among vaccinated children (direct effects only) and the 
entire population while including indirect (herd) effects. Epidemiological data from 
Greek published studies and the National Statistical Service were supplemented by 
expert panel opinion and international literature. Published costs from the Athens 
University Paediatric Hospital and government price bulletins were employed, assum-
ing price parity between PCV7 and PCV13. Only hospital treatment costs were con-
sidered and outcomes were discounted at 3%.     RESULTS: Immunization with PCV7, 
PCV10, and PCV13 would eliminate 74%, 82%, and 89% of IPD among vaccinated 
children, respectively. Assuming 84% vaccination rate with the recommended 31 
dose schedule and adding indirect beneﬁts, PCV13v vaccination would reduce IPD 
incidence by 63% in the total population versus no vaccination and would prevent 
an additional 6 and 4 deaths annually compared to PCV7/10 respectively. PCV13 
vaccination would annually save a158K or a189K versus PCV7 and PCV10 respec-
tively estimating only direct beneﬁts, and a803K or a2324K respectively including 
indirect effects. Compared to no vaccination annual cost savings reached a2403K 
(a903K if considering only direct beneﬁts). CONCLUSIONS: Introducing PCV13 in 
the Greek National Immunization schedule would provide additional protection 
against pneumococcal disease and cost savings for the health care system vs. existing 
PCV vaccines.
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OBJECTIVES: Persons with chronic hepatitis B virus infection (HBV) are at risk of 
developing cirrhosis and hepatocellular carcinoma. Early detection of chronic HBV 
infection through screening and treatment of eligible patients has the potential to 
contribute to secondary prevention of HBV. We assessed the costs-effectiveness of 
systematic screening for chronic hepatitis B (CHB) of ﬁrst generation migrants in The 
Netherlands from intermediate and high endemic countries. METHODS: Epidemio-
logical data of expected numbers of patients with active CHB in the target population 
and data on the costs of a screening program were combined with the outcomes of a 
Markov model in terms of costs and QALYs for patients with and without treatment, 
using a life time horizon. The base-case assumptions were an HBV prevalence of 
3.35%, 35% participation in screening, specialist consultation for 58% of patients 
selected for referral, and 75% of eligible patients starting treatment. RESULTS: 
Compared to the status quo, a one-time screening can reduce mortality of liver related 
diseases by 10%, from 1073 to 965 deaths. Using base case estimates, the incremental 
cost effectiveness ratio (ICER) of screening compared to the status quo is a8966 per 
QALY gained. The ICER varied between a7,936 and a11,705 per QALY gained in 
univariate sensitivity analysis, varying parameter values of HBV prevalence, participa-
tion rate, successful referral and treatment compliance. In multivariate sensitivity 
analysis for treatment effectiveness the ICER varied between a7,222 and a15,694, and 
for disease progression in natural history from a5,568 to a60,418. CONCLUSIONS: 
Early detection and treatment of eligible patients has a large impact on liver related 
health outcomes. A systematic screening program for chronic HBV infection targeted 
at ﬁrst generation migrants is likely to be cost effective, even at low estimates for the 
HBsAg prevalence, participation, referral and treatment compliance.
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OBJECTIVES: To determine the cost effectiveness of Pegatron combination therapy 
compared with no treatment for Australian patients who have failed an initial attempt 
at interferon-based (pegylated or non-pegylated) therapy. METHODS: The structure 
of the Markov model, utility values and transition probabilities were based on the 
literature. SVR and virologic response rates by genotype and ﬁbrosis were obtained 
from EPIC3 (Evaluation of PegIntron in Control of Hepatitis C Cirrhosis). EPIC3 is 
a large, prospective, multiphase clinical program evaluating the retreatment of chronic 
Hepatitis C patients with signiﬁcant ﬁbrosis/cirrhosis in whom previous treatment 
with nonpegylated or PEG-IFN alfa plus ribavirin was ineffective (ie, patients experi-
enced virologic nonresponse or relapse). Resource utilization was determined by a 
modiﬁed Delphi approach for various CHC health states. The population parameters 
used in the model reﬂect the mix of moderate and cirrhotic patients infected with dif-
ferent HCV genotypes, local medical management protocols, liver transplantation 
rates, and age-speciﬁc mortality rates of CHC patients in Australia. RESULTS: In the 
trial (N  1336), SVR was achieved by 22.6% (99% CI 19.7–25.6) of subjects. Of 
the 499 subjects with undetectable HCV-RNA viral load after 12 weeks of treatment, 
56.5% (95% CI 52.2–60.9) achieved an SVR. After discounting of costs and outcomes 
and extending to a life-time model, the modelled ICER was $12,887 Australian dollars 
per QALY gained. Sensitivity analyses indicated that when parameters are varied 
across reasonable ranges of their base case values, the ICER ratios range from cost 
saving to less than $50,000 per QALY gained. CONCLUSIONS: Based on clinical 
evidence, Pegatron treatment for patients who have failed prior interferon alfa com-
bination therapy is highly cost-effective relative to no treatment. Thus, allowing one 
course of retreatment for individuals who have failed an initial attempt at interferon 
alfa-based therapy is a cost effective approach to preventing further extension of the 
Hepatitis C epidemic in Australia.
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OBJECTIVES: To assess the cost-effectiveness of palivizumab as a preventive treat-
ment against respiratory syncytial virus (RSV) infection in children with congenital 
heart disease (CHD) in Korea. METHODS: A decision analytic model was developed 
to determine cost-effectiveness of prophylaxis with 5 monthly doses of palivizumab 
injection as compared to no prophylaxis. The analysis was based on a lifetime follow-
up period to capture the impact of palivizumab on long-term morbidity and mortality 
resulting from RSV infection. Efﬁcacy of prophylaxis was measured as the number of 
RSV hospitalizations and mortality avoided, and derived from literature. Prophylaxis 
cost was deﬁned as a sum of drug acquisition costs and costs associated with outpa-
tient visits occurred to receive palivizumab injection. Average cost for a hospitalization 
with RSV was calculated on the basis of 40 conﬁrmed cases of RSV hospitalization 
occurred between 2006 and 2008 from the two hospitals participated in this study. 
Future costs and effectiveness were discounted at 5%. RESULTS: In children with 
CHD, prophylaxis with palivizumab compared with no prophylaxis had an incremen-
tal cost-effectiveness ratio of 12.0 million Korean won (KW, 1 US dollar is approxi-
mately equal to 1000 KW) per life year gained (LYG) and 6.9 million KW per LYG 
from payer’s and societal perspective, respectively. One-way sensitivity analyses and 
scenario analysis conﬁrmed the robustness of the model. CONCLUSIONS: The esti-
mated ICER of palivizumab is within the generally accepted willingness-to-pay thresh-
old of ICER in Korean society. Thus, the use of palivizumab is considered cost-effective 
in children with CHD in Korea.
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OBJECTIVES: Varicella (chickenpox) affects most people and imposes an important 
burden on health care systems. It is, however, a preventable disease with childhood 
mass vaccination. The cost-effectiveness in France of replacing routine MMR with 
MMRV (Measles, Mumps, Rubella and Varicella) vaccine was explored. METHODS: 
The epidemiology of varicella and consequences of implementing different vaccination 
programs were investigated using an age-structured dynamic model. The basecase 
assumed one dose protects for 17 years and two doses for three times longer and no 
natural immunity boosting. MMRV vaccination was assumed to replace up to 80% 
of MMR over 5 years. An alternative scenario was analysed to assess the impact of 
an improved MMRV vaccination coverage (replacement of 100% of MMR over a 2-
year period plus a catch up program for eight years in 5-year olds). A MMRV vaccine 
price of a54 per dose was assumed. RESULTS: In the basecase, varicella incidence 
decreased from 12,707 per million person-years before vaccination to 4,746 after 30 
years of vaccination (steady state). With fewer varicella cases and associated complica-
tions, annual outpatient and hospital costs decrease by 32%. The cost per quality-
adjusted life year (QALY) gained after 30 years was a3347 (95%CI 1; 9927). With 
the scenario of improved vaccination coverage, varicella incidence decreased to 2,085 
per million person-years and the cost per QALY was estimated at a3284 (95%CI 15; 
8916) after 30 years of vaccination. If a societal perspective is considered (including 
lost productivity costs), both the basecase and alternative vaccination scenario pro-
duced more QALYs and cost-savings. CONCLUSIONS: Gradual and partial replace-
ment of MMR with MMRV vaccination is predicted to dramatically decrease varicella 
incidence, and, to be highly cost-effective from a payer perspective and cost-saving 
from a societal perspective. A more intensive MMRV coverage is predicted to further 
reduce varicella incidence while remaining a highly cost-effective vaccination 
strategy.
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OBJECTIVES: To Demonstrate that doripenem is a cost-effective option compared 
with the most utilized treatments in patients with Ventilator-Associated Pneumonia 
(VAP) in Mexico, from the point of view of the Mexican Institute of Social Security 
(IMSS). METHODS: A decision tree was elaborated for patients with VAP. Patients 
were assumed to be treated with doripenem, imipenem or piperacilin-tazobactam (PT) 
